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Abstract: Genome-wide association studies (GWAS) have identified an abundance of genetic loci
associated with complex traits and diseases. In contrast, in-depth characterization of an individual
genetic signal is rarely available. Here, we focus on the genetic variant rs2168518 in 15q24.1
previously associated with age-related macular degeneration (AMD), but only with suggestive
evidence. In a two-step procedure, we initially conducted a series of association analyses to further
delineate the association of rs2168518 with AMD but also with other complex phenotypes by using
large independent datasets from the International AMD Genomics Consortium (IAMDGC) and
the UK Biobank. We then performed a functional annotation with reference to gene expression
regulation based on data from the Genotype-Tissue Expression (GTEx) project and RegulomeDB.
Association analysis revealed a gender-specific association with male AMD patients and an association
predominantly with choroidal neovascularization. Further, the AMD association colocalizes with
an association signal of several blood pressure-related phenotypes and with the gene expression
regulation of CYP1A1, a member of the cytochrome P450 superfamily of monooxygenases. Functional
annotation revealed altered transcription factor (TF) binding sites for gender-specific TFs, including
SOX9 and SRY. In conclusion, the pleiotropic 15q24.1 association signal suggests a shared mechanism
between blood pressure regulation and choroidal neovascularization with a potential involvement
of CYP1A1.
Keywords: age-related macular degeneration; choroidal neovascularization; pleiotropy; miRNA
variant; eQTL; locus analysis; gender specificity
1. Introduction
Over the past 15 years, genome-wide association studies (GWAS) have revolutionized research
into complex diseases and have led to an increasingly comprehensive knowledge about their genetic
fundamentals. While the first successful GWAS was on age-related macular degeneration (AMD),
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describing a reproducible locus on the long arm of chromosome 1 [1], the most recent AMD GWAS
reported 34 loci harboring 52 independent genetic lead signals with genome-wide significance [2].
Despite having generated a refined map of loci contributing to AMD pathology, follow-up studies,
which investigate the biological mechanisms underlying the statistical associations, are still greatly
missing. Not surprisingly, AMD-related research mainly focuses on CFH and ARMS2/HTRA1, two loci,
which display the largest effect sizes for AMD risk [2,3].
While GWAS approaches follow an unbiased strategy, targeted association studies have the
advantage to provide an improved statistical power while focusing on genetic variants or genes for
which further information on possible disease-related aspects are available. To this end, one category
of promising genes are microRNAs (miRNAs), which are considered excellent disease biomarkers [4]
and even encouraging therapeutic targets [5,6], specifically for complex diseases. MiRNAs are small
post-transcriptional regulators by incorporating into the RNA-induced silencing complex (RISC),
which binds to mRNA transcripts in the cytosol and contributes to their degradation or translational
repression [7]. Of special interest is the seed region of the mature miRNA, a key feature for target gene
recognition and binding [8,9]. Genetic variants located in miRNAs could therefore be of functional
importance as these may influence gene expression regulation and thus contribute to a pathological
phenotype. Using a targeted association analysis for miRNA variants, Ghanbari and colleagues (2017)
identified an association of AMD with the genetic variant rs2168518, which is located in the seed region
of hsa-mir-4513 [10]. A recent meta-analysis of AMD further supported the association of this variant
with AMD [11].
Interestingly, the miRNA seed variant rs2168518 seems to have a pleiotropic effect as it has been
linked to several complex traits and diseases, including cardiometabolic phenotypes, the clinical
outcome in coronary artery disease and prognosis of lung adenocarcinoma [12–15]. However, so far,
the potential mechanism behind these associations has always been limited to the obvious candidate,
the hsa-mir-4513 gene itself. Here, we aimed to analyze in-depth the AMD-associated 15q24.1 interval
harboring the rs2168518 signal. We have performed a series of analyses to investigate the association
with AMD and to elucidate its pleiotropic nature. Furthermore, we have carried out several analyses to
functionally characterize this locus with regard to gene expression regulation and transcription factor
(TF) binding.
2. Materials and Methods
2.1. Availability of Datasets
The dataset from the Resource for Genetic Epidemiology Research on Adult Health and Aging
(GERA) cohort, a sub-study of the Research Program on Genes, Environment, and Health (RPGEH),
is available at the database of genotypes and phenotypes (dbGap) under the accession number
phs000674.v3.p3 and phs000788.v2.p3, respectively. The data permitted for sharing by the respective
institutional review boards from the International AMD Genomics Consortium (IAMDGC) is available at
dbGap under the accession number phs001039.v1.p1. The dataset from the Genotype-Tissue Expression
Project (GTEx) is available at dbGap under the accession number phs000424.v8.p2. Processed gene
expression data of GTEx can be downloaded at www.gtexportal.org. The UK Biobank dataset can be
obtained upon application (ukbiobank.ac.uk). This research has been conducted using the UK Biobank
Resource under application number 44862. GWAS summary statistics of the UK Biobank data are
publicly available at http://www.nealelab.is/uk-biobank/.
2.2. Description of Datasets
In total, data from 63,156 individuals, 19,018 AMD patients and 44,138 control individuals,
were included to investigate the association of rs2168518 with AMD. To this end, data from the
GERA cohort and the IAMDGC were jointly analyzed. The GERA cohort includes 2874 AMD
patients and 26,306 control individuals only from European descent and born before 1948. The GERA
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dataset comprises 12,734 males and 16,446 females. Detailed information on array design [16],
genotyping process and quality control (QC) [17], and imputation [18] is available. Further, data
from the IAMDGC with 16,144 late-stage AMD patients and 17,832 control individuals were used.
Unrelated individuals of the IAMDGC study were of European descent and included 14,352 males
and 19,624 females. Subphenotypes within the late-stage AMD samples were 10,749 choroidal
neovascularization AMD (CNV), 3235 geographic atrophy AMD (GA), and 2160 patients with CNV
and GA combined. The IAMDGC data additionally contain 6657 individuals with early or intermediate
AMD, which were included in the early AMD association analysis. Detailed information about gender
distribution in the different subgroups are available in Supplementary Table S1. Detailed information
about selection criteria, ophthalmological grading, QC of the genetic data, and imputation procedures
were described in detail elsewhere [2].
To investigate the pleiotropic nature of rs2168518, we explored its association with multiple
phenotypes as given in the UK Biobank dataset with publicly available GWAS summary statistics
of the 2419 phenotypes available [19]. Summary statistics were evaluated for both sexes for a total
of 361,194 individuals, and separately for females (n = 194,174) and males (n = 167,020). Further,
we directly used UK Biobank data to extract specific phenotype information. In our analysis, only
self-reported white individuals were included, and related individuals up to the third degree of kinship
were excluded, as well as individuals with inconsistencies in self-reported sex and genetic sex. In total,
379,356 individual raw datasets remained in the study, including 204,527 females and 174,829 males.
Calculation of expression quantitative trait loci (eQTL) was performed in the GTEx data version 8.
The detailed data processing protocols for the GTEx project are described elsewhere [20]. A genotype
principle component analysis based on 100,000 randomly selected genetic variants from the GTEx whole
genome sequencing data and the corresponding genotype information of the 1000 Genomes Project
reference panel (Phase 3, release 20130502) [21] was conducted using the snpgdsPCA package [22]
in R [23]. The first two principal components were plotted to determine the ethnicity. Only samples
clustering next to the European reference individuals remained in the study, leaving 694 individuals
(237 females and 457 males) for eQTL analysis. Sample sizes for the 49 analyzed tissues varied between
65 (see “kidney cortex”) and 584 (see “muscle skeletal”).
2.3. Association of rs2168518 with AMD
To investigate the association of rs2168518 with AMD, a combined analysis of the IAMDGC and
GERA data was performed. Prior to analysis, genetic information of rs2168518 was extracted from
the IAMDGC dataset. In the GERA dataset, genetic information of rs1378942, a proxy in full linkage
disequilibrium (LD) with rs2168518, was extracted. Genetic information was converted to dosages.
To calculate the association with AMD in the GERA and IAMDGC dataset, a logistic regression model
was applied by using the glm function implemented in R [23], with adjustments for dataset and gender.
The p-value threshold was set to 5 × 10−8 to identify genome-wide significant associations in the
combined analysis.
Association analysis with different subgroups of AMD was performed exclusively in the IAMDGC
dataset. A logistic regression model was applied as described above. The list of co-variates included
age, gender, the first two genotype principal components, as well as the source of DNA. P-values were
adjusted for multiple testing according to the false discovery rate (FDR, Q-value) [24] as implemented
in the multtest package [25].
For the conditional analysis, a logistic regression model was used including all late-stage AMD
samples of the IAMDGC dataset and adjusted for all covariates from the subgroup analysis. The analysis
was further adjusted for the genetic variant with the smallest p-value of AMD association in the region
of interest (rs11072508, R2 to rs2168518 = 0.903 in Europeans).
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2.4. Haplotype Distribution over Different Populations
To investigate the allele frequency distribution of rs2168518 in different populations, all genetic
variants in LD with rs2168518 (defined as R2 > 0.8 in Europeans) were extracted via the LDproxy tool
from LDlink [26,27] (Supplementary Table S2). In total, 26 genetic variants were identified and used to
investigate haplotype differences in various populations using the LDhap tool from LDlink. One variant
(rs36117428) was excluded from the haplotype analysis due to missing data in the reference panel.
2.5. Phenome-Wide Association Analysis of rs2168518 in the UK Biobank Database
To investigate the association of rs2168518 with defined phenotype we used the preliminary UK
Biobank PheWeb, which was based on the first Neale lab analysis available at the PheWeb browser [28].
PheWeb compromises GWAS results of 2419 phenotypes and is based on data of ~337,000 unrelated
British individuals from the UK Biobank dataset [29]. All associations of rs2168518 below the p-value
threshold of 10−4 were extracted. This filter resulted in 15 phenotype associations with rs2168518.
Further, the association of rs2168518 with trait “Eye problems/disorders: Macular degeneration” was
retested as it was not among the initial list of 15 phenotypes identified. GWAS summary statistics
of UK Biobank data for the 15 significant phenotypes, and for “Eye problems/disorders: Macular
degeneration”, were downloaded from http://www.nealelab.is/uk-biobank/ [19]. We retrieved summary
statistics for GWAS from both sexes, as well as for female and male separately. Locuszoom plots [30,31]
were generated to visualize the GWAS summary statistics. These plots were used to manually narrow
the region of interest for all 16 phenotype associations to a region of 0.6 Mbp (Chromosome 15:
75,000,000–75,600,000, GRCh37). It should be noted that this cutoff was chosen to ensure inclusion of
all association signals of the phenotypes included in the study.
2.6. Colocalization Analysis Based on the UK Biobank GWAS Summary Statistics
We performed colocalization analyses to test for gender specificity based on the UK Biobank
summary statistics. This analysis was performed using the coloc package [32] in R [23] by comparing
GWAS results from females and males of the same phenotype in the refined genomic region. Coloc
probabilities indicate whether the association signal is found for one trait only, and not for others
(in our case with male or female individuals). Probability thresholds of > 0.8 were applied for filtering
the results.
2.7. Colocalization Analysis of the Genetic Signals Underlying UK Biobank Associations and AMD
A colocalization analysis using coloc was performed to test for correlation of AMD association
signals in the IAMDGC dataset with phenotypes from the UK Biobank dataset. To this end, coloc
requires association results, information about the proportion of cases for continuous phenotypes
and the phenotype standard deviation for quantitative traits. For continuous traits at UK Biobank,
the number of missing samples in the GWAS summary statistics for the respective phenotype were
reported exclusively with sexes merged. To estimate the number of missing samples for females
and males separately, we utilized the total sample size of the respective gender-specific GWAS and
deducted the number of missing individuals of the respective phenotype divided by 2 with the
assumption, that the missing individuals were spread evenly across the two sexes. Standard deviations
for quantitative traits were retrieved either from the initial assessment visit of the UK Biobank Data
Showcase [33] (for “Creatinine (enzymatic) in urine” and “Sodium in urine”) or directly from UK
Biobank data concerning diastolic blood pressure (automated reading, DBP) and systolic blood pressure
(automated reading, SBP). The latter two traits were determined for both sexes and separately for
females and males.
Coloc probabilities indicate whether there is an association in the respective genomic region for
both traits. In this study, we used probability thresholds of > 0.8.
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2.8. eQTL Calculation
eQTL calculations were performed for all 49 tissues provided by GTEx (version 8) [20]. Phased
genotypes were converted into allele dosages and a minor allele frequency threshold of 1% was applied.
Local eQTL were calculated based on linear regression models using FastQTL (version v2.184_gtex) [34]
and an arbitrary window of 1 Mbp up- and downstream of the variant or gene of interest was selected.
We first identified genes potentially regulated by rs2168518 using an exploratory p-value < 10−4.
Thereafter, we calculated all local eQTL for the significant rs2168518 eQTL genes (eGenes). These results
were then used for colocalization analyses regarding other eQTL or GWAS signals. Further, by miRWalk
3 [35,36], we examined whether identified eGenes are predicted target genes of hsa-mir-4513.
2.9. Identification of Transcription Factor Binding Sites
All genetic variants in LD with rs2168518 (defined as R2 > 0.8 in Europeans, Supplementary
Table S2) were analyzed regarding their impact on TF binding by RegulomeDB 2.0 [37,38]. Variants
with a RegulomeDB rank < 3 were selected for further investigations.
3. Results
3.1. Association of rs2168518 with AMD
3.1.1. Validation of a Genome-Wide Significant Association of rs2168518 with AMD
A recent meta-analysis considering three datasets reported a genome-wide significant association
of AMD with rs1378940, a proxy variant of rs2168518 (R2 = 1 in European individuals) [11]. However,
this study did not follow a classical GWAS approach, but instead relied on a multivariate GWAS model
introduced as multiple trait analysis of GWAS (MTAG) [39]. For this, only summary statistics were
used and more critical datasets that are not entirely independent. We therefore wanted to validate the
association of rs2168518 with AMD in the original and independent data from the IAMDGC and GERA
cohorts. In both datasets, a nominal association with AMD was observed (p-value IAMDGC = 3.05 ×
10−6 and GERA = 3.88 × 10−3). Combining the two datasets provided the statistical power to reach
genome-wide significance of an association of AMD with rs2168518 (p-value = 4.52 × 10−8) (Figure 1).
Figure 1. Genome-wide association of age-related macular degeneration (AMD) with rs2168518. The
association was calculated separately in the International AMD Genomics Consortium (IAMDGC)
and Genetic Epidemiology Research on Adult Health and Aging (GERA) datasets, as well as in the
combined data where the association of AMD with rs2168518 displays genome-wide significance
(p-value < 5 × 10−8). For all associations, the A allele indicates the effect allele. OR = odds ratio,
CI = confidence intervals, n = sample size.
3.1.2. Refinement of the Genetic Association Signal with AMD
To further characterize the potential influence of rs2168518 on AMD, we calculated its association
with AMD subtypes including late-stage AMD, GA, CNV, GA and CNV combined, as well as early
stage AMD (Table 1).
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Table 1. Association of rs2168518 with AMD subtypes in the IAMDGC dataset. For all associations,
the A allele indicates the effect allele. Associations were calculated in comparison with the respective
non-AMD individuals. Q-values < 0.05 are indicated in bold.
Sample Size OR [95% CI] p-Value Q-Value
Late-stage AMD 33,976 1.089 [1.052–1.127] 8.74 × 10−7 4.00 × 10−6
Geographic atrophy (GA) 21,067 1.077 [1.016–1.142] 0.013 0.024
Choroidal neovascularization (CNV) 28,581 1.091 [1.050–1.133] 8.29 × 10−6 1.87 × 10−5
GA & CNV 19,992 1.073 [1.001–1.150] 0.048 0.054
Early stage AMD 24,489 1.036 [0.992–1.081] 0.112 0.112
<75 years 17,326 1.121 [1.066–1.177] 7.41 × 10−6 1.87 × 10−5
>75 years 15,825 1.055 [1.005–1.108] 0.030 0.039
Male 14,352 1.139 [1.081–1.200] 8.89 × 10−7 4.00 × 10−6
Female 19,624 1.053 [1.007–1.102] 0.025 0.038
OR = odds ratio, CI = confidence intervals, Q-value = false discovery rate (FDR)-corrected p-value.
This revealed an association of rs2168518 with late-stage AMD, GA, and CNV (Q-value < 0.05).
No association was detected between rs2168518 and the combined GA and CNV phenotype. However,
the number of individuals in this subgroup was relatively small with 2160 cases and therefore statistical
power might be insufficient. Comparison of the two other late-stage AMD subtypes revealed, that
the association with GA (Q-value = 0.024) was weak in comparison to the association with CNV
(Q-value = 1.87 × 10−5). Further, we separated the IAMDGC dataset into individuals younger and
older than 75 years of age. Interestingly, the association of rs2168518 with AMD was evident in the
group of individuals under the age of 75 (Q-value = 1.87 × 10−5). Dividing the IAMDGC dataset
according to gender revealed rs2168518 to be strongly associated with AMD in males (Q-value =
4.00 × 10−6), but only weak with AMD in females (Q-value = 0.038) (Figure 2).
Figure 2. Association of rs2168518 with AMD in males and females. The association with late-stage
AMD was calculated separately for both sexes in the IAMDGC dataset. While an association signal
with AMD can be detected in males, an association in females is missing. Rs2168518 is presented as
purple diamond and serves as linkage disequilibrium (LD) reference variant. Plots were created with
Locuszoom [30]. n = sample size.
This finding is strengthened by the fact, that the female sample sizes were larger (n AMD cases =
9612, n controls = 10,012) in comparison to the male sample sizes (n AMD cases = 6532, n control =
7820). Taken together, rs2168518 reveals a gender-specific CNV-related association with AMD, most
strongly when under the age of 75 years.
A conditional analysis was done to clarify whether the AMD association signal at the 15q24.1 locus
consists of one or more genetic signals. As a result, no further variants were significantly associated
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with AMD, suggesting that the association with AMD at this locus was conferred exclusively by a
single signal (Supplementary Figure S1).
3.2. Haplotype Distribution in Populations
Next, we tested whether rs2168518 exhibits a population-specific effect. We defined haplotypes
based on all genetic variants in LD with rs2168518 (R2 > 0.8 in Europeans, Supplementary Table S2).
This resulted in seven haplotypes, H1 to H7 (Supplementary Table S3). Interestingly, haplotype
frequencies varied widely between populations (Table 2).
Table 2. Haplotype distribution of genetic variants in LD (R2 > 0.8 in Europeans) with rs2168518 in
different populations. Haplotype frequencies were calculated with the LDhap tool from LDlink [26,27].
Haplotype rs2168518 Allele EUR EAS SAS AFR
H1 A 0.5577 0.1508 0.1483 0.0257
H2 G 0.3429 0.5149 0.7321 0.7973
H3 G 0.0268 0.2788 0.0828 0.0408
H4 A 0.0109 - - -
H5 A - 0.0169 - -
H6 G - - - 0.0983
H7 G - - - 0.0106
EUR = European population, EAS = East Asian population, SAS = South Asian population, AFR = African population.
The haplotype H1, which contains the rs2168518 AMD risk allele “A”, showed by far the highest
allele frequency in Europeans (55.77%). In contrast, H2 is the most frequent haplotype in other
populations. Our results show that only a minority of the Asian and African populations carry the
rs2168518 AMD risk allele.
3.3. Pleiotropic Effect of rs2168518 Assessed in the UK Biobank Data
To investigate a pleiotropic effect of rs2168518, we used the PheWeb browser [28] containing
GWAS results of over 2000 phenotypes in the UK Biobank dataset. We applied an exploratory threshold
for significance (p-value < 10−4) and detected significant associations of rs2168518 with 15 phenotypes,
of which eight reach genome-wide significance (p-value < 5 × 10−8) (Table 3, Supplementary Table S4).
We manually catalogued the significant phenotypes into related groups and investigated
gender-specificity and colocalization with the IAMDGC AMD signal.
The UK Biobank phenotype code for AMD “Eye problems/disorders: Macular degeneration”
failed to reach the set p-value threshold, which may be attributed to the low sample size of AMD
patients in the UK Biobank cohort. The association analysis was performed with almost 109,000 samples
stated by the PheWeb browser [28], while the actual version of UK Biobank reports approximately
5000 self-reported AMD cases according to data field 6148 in the UK Biobank Data Showcase [33].
3.3.1. Association of rs2168518 with Blood Pressure Phenotypes
The majority of significant phenotypes, 10 out of 15, were assigned to one of the blood
pressure-related groups (Table 3). The AMD risk increasing “A” allele of rs2168518 displays a
consistent protective effect on high blood pressure measurements, including DBP, SBP, and hypertension.
This was supported by significant associations with the same effect direction of indirect hypertension
measurements including the treatment with Ramipril (“Treatment/medication code: ramipril”) and
bendroflumethiazide (“Treatment/medication code: bendroflumethiazide”). In addition, GWAS with
focus on control individuals in these groups (“Vascular/heart problems diagnosed by doctor: None of
the above”, “Medication for cholesterol, blood pressure or diabetes: None of the above”) displayed
adverse effect sizes for the same allele.
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Table 3. Association of rs2168518 in the UK Biobank genome-wide association studies (GWAS) summary
statistics. Fifteen phenotypes display a significant association with rs2168518 (p-value < 1 × 10−4) in
the UK Biobank PheWeb browser [28]. The association of rs2168518 with Macular Degeneration failed
to reach the Table 19. Gender specificity (probability > 0.8 in one gender) was defined by comparison
of the association signal in males and females in the UK Biobank summary statistic results using
colocalization. Further, a colocalization of the respective signal with the late-stage AMD signal in
the IAMDGC dataset (both sexes) was calculated. Coloc probabilities for “one signal” indicate that
the same genetic signal underlies the association with AMD and the respective phenotype, while
probabilities for “two signals” indicate that different genetic variants are underlying the associations.














1.50 × 10−23 both sexes 2.27 × 10−27
no
0.604 0.385
female 7.27 × 10−18 0.964 0.035
male 2.58 × 10−11 0.610 0.379
Vascular/heart problems
diagnosed by doctor: high
blood pressure
7.20 × 10−23 both sexes 2.24 × 10−26
no
0.976 0.024
female 2.89 × 10−14 0.918 0.079
male 9.90 × 10−14 0.970 0.029
Vascular/heart problems
diagnosed by doctor: none of
the above
2.60 × 10−21 both sexes 2.79 × 10−25
no
0.970 0.029
female 9.10 × 10−14 0.860 0.136
male 4.11 × 10−13 0.969 0.030
Non-cancer illness code,
self-reported: hypertension
2.70 × 10−21 both sexes 2.15 × 10−24
no
0.975 0.024
female 3.15 × 10−13 0.936 0.062
male 9.12 × 10−13 0.965 0.034
Systolic blood pressure,
automated reading
1.60 × 10−11 both sexes 9.33 × 10−14
no
0.735 0.258
female 1.12 × 10−10 0.969 0.030
male 7.66 × 10−5 0.428 0.523
Medication for cholesterol,
blood pressure or diabetes:
blood pressure medication
6.30 × 10−11 male 3.63 × 10−12 0.938 0.061
Medication for cholesterol,
blood pressure, diabetes, or
take exogenous hormones:
blood pressure medication
3.90 × 10−10 female 8.58 × 10−12 0.890 0.106
Creatinine (enzymatic) in urine
5.30 × 10−9 both sexes 2.85 × 10−7
no
0.037 0.936
female 8.92 × 10−8 0.038 0.934
male 0.031 0.037 0.936
Treatment/medication code:
ramipril




female 0.103 0.034 0.067
male 4.03 × 10−8 0.898 0.099
Treatment/medication code:
bendroflumethiazide
1.20 × 10−7 both sexes 5.29 × 10−8
no
0.948 0.051
female 9.58 × 10−6 0.901 0.080
male 1.37 × 10−3 0.486 0.085
Medication for cholesterol,
blood pressure or diabetes:
none of the above
1.30 × 10−7 male 1.23 × 10−8 0.830 0.165
Hearing difficulty/problems
with background noise




female 6.01 × 10−9 0.966 0.033
male 0.345 0.007 0.062
Birth weight of first child 1.20 × 10−5 female 2.48 × 10−5 0.785 0.175
Mineral and other dietary
supplements: glucosamine
2.50 × 10−5 both sexes 3.59 × 10−5
no
0.877 0.068
female 9.41 × 10−3 0.118 0.098
male 8.17 × 10−4 0.469 0.056
Sodium in urine
7.20 × 10−5 both sexes 8.38 × 10−4
no
0.037 0.935
female 1.58 × 10−3 0.037 0.935
male 0.106 0.010 0.300
Eye problems/disorders:
macular degeneration
5.10 × 10−3 both sexes 2.66 × 10−3
female 0.157
male 2.82 × 10−3
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Interestingly, only the association signal of Ramipril treatment displays a gender-specific
association signal in this group with rs2168518 being associated with Ramipril treatment exclusively in
males (p-value = 4.03 × 10−8), while there is no association of rs2168518 with Ramipril-treated females
(p-value = 0.103).
The colocalization analysis with AMD shows that the association signal underlying the blood
pressure GWAS is identical to the AMD association in the IAMDGC cohort (coloc probabilities for the
same signal > 0.8, Figure 3).
Figure 3. Locuszoom plots of the association signals in late-stage AMD (IAMDGC), “Vascular/heart
problems diagnosed by doctor: High blood pressure” (UK Biobank) and “Creatinine in urine”
(UK Biobank). The genetic association signal of AMD represents the same genetic signal as for the
blood pressure association (coloc probability = 0.976), while the “UKB creatinine in urine” association
underlies a different genetic signal (coloc probability = 0.037). Rs2168518 is presented as a purple
diamond and serves as LD reference variant. Plots were created with Locuszoom [30].
This is the case for most of the phenotypes in all sub-studies (both sexes, as well as female and
male) in comparison with AMD (both sexes and male). Exceptions are DBP and SBP, which only
display a coloc probability > 0.8 with AMD in females.
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3.3.2. Association of rs2168518 with Metabolic Products in Urine
A second group of rs2168518-associated traits can be formed by metabolic products in urine,
creatinine (“Creatinine (enzymatic) in urine”), and sodium (“Sodium in urine”). The “A” allele of
rs2168518 showed a protective association with both phenotypes against high creatinine/sodium levels
in the urine. There was no difference in the association signal between females and males. Interestingly,
the colocalization analysis with AMD revealed that the association signal for both phenotypes was a
different genetic signal than for AMD (coloc probability for different genetic signals > 0.8, Figure 3).
3.3.3. Association of rs2168518 with Other Phenotypes
In the UK Biobank cohort, three further phenotypes were significantly associated with rs2168518
(p-value < 10−4). Strikingly, the phenotype “Hearing difficulty/problems with background noise”
showed a gender-specific difference in its association with rs2168518 opposite to AMD with a
strong association in females (p-value = 6.01 × 10−9) and no association in males (p-value = 0.345).
The colocalization analysis in females and males further supports this finding (probability for a
signal in females only = 0.886). The genetic association signal for the UK Biobank phenotypes
“Hearing difficulty/problems with background noise” (both sexes and females only) and “Mineral and
other dietary supplements: Glucosamine” (both sexes) both colocalized with the IAMDGC AMD
signal (both sexes and males only).
3.4. Local eQTL Analysis of rs2168518 in the GTEx Dataset
Next, we investigated whether rs2168518 has an impact on gene expression regulation. A local
eQTL analysis was conducted in 49 tissues as given in the GTEx project. An exploratory p-value
threshold of 10−4 resulted in 93 eQTL of rs2168518 and 14 eGenes across all tissues (Supplementary
Table S5). Seven of the eGenes displayed a rather tissue-specific eQTL in less than five tissues and
showed mostly moderate p-values (p-value > 10−7 for 5 out of 7 eGenes). In contrast, the smallest
p-value with 3.78 × 10−33 displays RPP25 (see “artery tibial”), which is a significant eGene in 17 tissues.
We further calculated eQTL by separating male and female data and compared their association
signals by a colocalization analysis. A preliminary interpretation of these results failed to show a
gender-specific effect on gene expression regulation. An interpretation of these results should be made
with caution due to an uneven gender distribution in the GTEx dataset (237 females vs. 457 males).
3.4.1. eGenes Are Not Regulated by hsa-mir-4513
To investigate the probability that eGenes are regulated by hsa-mir-4513, we used miRWalk 3 [35,36]
to predicted target genes of the respective miRNA. Some eGenes exhibit potential hsa-mir-4513 binding
sites, but none of these genes were a validated target defined by miRTarBase [40]. The prediction tools
TargetScan [41] and miRDB [42] did not suggest the eGenes as targets of hsa-mir-4513 (Supplementary
Table S6). Therefore, it appears unlikely that hsa-mir-4513 was responsible for the observed effects on
gene expression regulation in this region.
3.4.2. Colocalization of eGenes
Beside a classical eQTL analysis, a colocalization analysis of eGenes was performed to investigate
whether the respective eGenes were regulated by the same genetic signal. This analysis was performed
for all tissues separately that display at least two local eQTL regarding rs2168518. We observed three
gene pairs, which were regulated by the same genetic signal in at least two tissues (coloc probability >
0.8) (Supplementary Table S7). The gene pair that occurred most frequently was ULK3 and CSK in
four tissues, followed by RPP25 and SCAMP5 in three tissues, and SCAMP2 and MPI in two tissues.
An exemplary colocalization heatmap is shown in Supplementary Figure S2 for adipose subcutaneous
tissue, which displays most eQTL results.
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3.4.3. Colocalization with Phenotypes
To investigate whether an eQTL signal corresponds to the same genetic signal as a phenotype
association, a colocalization analysis of eQTL with the IAMDGC data and UK Biobank summary
statistics was performed. Overall, the signals of five eGenes correspond to the genetic signals,
which were also associated with AMD (Supplementary Table S8). Of these five eGenes, only one,
namely CYP1A1 (Figure 4), revealed a colocalization in more than two tissues.
Figure 4. Expression quantitative trait locus (eQTL) analysis reveals CYP1A1 as a potentially regulated
gene by the AMD-associated variant rs2168518. (A) As an example, the significant eQTL gene (eGene)
CYP1A1 is differentially regulated by rs2168518 in artery tibial tissue and (B) colocalizes with the
genetic association signal of AMD. Manhattan Plots were created with Locuszoom [30].
Furthermore, colocalization of CYP1A1 occured frequently with ten different blood pressure
phenotypes. However, for some of these phenotypes, this signal was not as sharply separated from
the other eGenes like for AMD. In these cases, CYP1A1 colocalized with the genetic association of the
respective phenotypes in combination with ULK3 and CSK.
In contrast to AMD and the blood pressure phenotypes, the association signal of “Birth weight of
the first child” colocalized clearly with RPP25 in several tissues. Whereas, the association signal of
“Creatinine in urine” and “Sodium in urine” failed to colocalize with any eQTL.
3.5. Functional Annotation of Genetic Variants at 15q24.1 with RegulomeDB 2.0
Variants in TF binding sites allow to address potential transcriptional regulation mechanisms.
We investigated whether genetic variants in LD with rs2168518 (R2 > 0.8 in Europeans, Supplementary
Table S2) have an impact on TF binding by Regulome DB 2.0 [37,38]. In total, eight of 27 variants
were ranked from Regulome DB to have a potential influence on TF binding or gene expression
regulation (RegulomeDB rank < 3, Supplementary Table S9). Two of them were predicted to have a
regulatory impact on ULK3 expression in monocytes, but showed little evidence to match TF motifs.
The remaining six variants were predicted to impact TF binding by matching DNase peaks and
footprints. Interestingly, one of these variants (rs11072507) altered a motif targeted by SRY and SOX9,
which play an important role in sex determination [43], and another variant (rs11636952) altered a
motif targeted by ZFX, a TF located on the X chromosome (Figure 5).
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Figure 5. Locus scheme of functional mechanisms within the AMD association signal. The Manhattan
plot represents the association p-values with late-stage AMD. rs2168518 is highlighted as a red diamond
and all variants strongly linked with rs2168518 (R2 > 0.8 in Europeans) are displayed as red dots.
Potentially altered transcription factor (TF) binding sites are shown with regard to the approximate
chromosomal position. TFs related to gender differences, due to their location on sex chromosomes
(SRY and ZFX) or because they are direct target genes of TFs located on sex chromosomes (SOX9),
are highlighted in red. Below the Manhattan Plot are schemes of eGenes colocalizing with the AMD
association signal and eGenes are displayed in regard to their approximate chromosomal position.
eGenes colocalizing with the AMD association signal in more than two tissues are highlighted in red.
As rs2168518 is located within hsa-mir-4513, the chromosomal position of this microRNA (miRNA) is
shown below the colocalizing eGenes with AMD. The raw version of the Manhattan Plot was created
with Locuszoom [30].
4. Discussion
Here, we report on an in-depth analysis of a recently described AMD-associated locus at
15q24.1 [10,11]. This locus gained a wider interest as it harbors a genetic variant, rs2168518, speculated
to modify hsa-mir-4513 function [10]. We first confirmed an earlier association of this locus with
AMD in a large independent dataset and determined genome-wide significance for rs2168518 with
AMD. We noticed a strong association of rs2168518 with the CNV complication in late-stage AMD
and, additionally, a marked gender-specificity for male AMD patients. Further, the rs2168518 risk
allele was found to be abundantly present in European individuals, but to a much lesser extent in an
Asian or African background. Searching for pleiotropic effects of rs2168518, we demonstrated that
colocalization of this genetic marker with GWAS summary statistics from over 2000 phenotypes at
UK Biobank points to signal overlaps specifically with high blood pressure phenotypes. This is in
line with a prior study [12], thus further supporting the importance of this locus for CNV genetics.
We then proceeded to functionally annotate the 15q24.1 locus. An eQTL analysis in the GTEx database
indicates that rs2168518 influences gene expression of 14 genes, seven of which with a measurable
effect in five or more tissues. One of the eGenes stands out based on its colocalization with AMD
and blood pressure association signals, namely CYP1A1. Notably, prediction tools to identify miRNA
target genes failed to suggest CYP1A1 as a target of hsa-mir-4513. This makes an indirect regulatory
effect of CYP1A1 through this miRNA unlikely. Finally, investigating TF binding provides a first clue
to a possible mechanism explaining the gender-specificity of the rs2168518 association with AMD by
suggesting an altered binding of gender-specific TFs.
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Genetic correlations of complex diseases are a well-known phenomenon [44,45], which have the
potential to uncover shared mechanistic processes between seemingly unrelated complex diseases.
Also, an association of rs2168518 with several phenotypes has been described before, including
cardiometabolic traits and the prognosis of lung adenocarcinoma [12–15]. Therefore, we were interested
to further investigate this potential pleiotropic effect of rs2168518. An initial test with UK Biobank
data revealed association of rs2168518 with several phenotypes, including blood pressure-related
phenotypes, hearing difficulty/problems with background noise, birth weight of the first child, and
metabolites in urine. Remarkably, a colocalization analysis revealed that only the blood pressure-related
phenotypes as well as hearing difficulty/problems with background noise association signals correspond
to the identical genetic signal as established for the AMD association. In contrast, the association signal
for metabolites in urine clearly failed to match the same signal. This highlights the importance to
consider the full spread of association signals at a defined locus instead of simply analyzing single
variant associations.
The genetics of AMD and blood pressure and the correlation between these two traits were
investigated by several studies [46–48]. In our own work, we established a combined protective
effect of hypertension-associated variants in AMD [48], which is in line with the results of the current
study. In contrast, phenotype association studies of AMD and hypertension pointed in the opposite
direction [46,47]. The latter two association studies suggested that there may be a difference in the
association between hypertension and CNV versus non-neovascular AMD. This in turn would indicate
different underlying pathomechanisms that are more similar to high blood pressure in CNV than
in non-neovascular AMD [46,47]. Such a hypothesis would fit our observations, namely that the
investigated locus is mainly associated with blood pressure-related phenotypes and CNV, and to a
lesser extent with other subtypes of AMD.
Often, genetic association studies simply focus on the discovery of association signals, while
deeper analyses into underlying mechanisms are regularly sparse. Nevertheless, it is exactly the insight
into such mechanisms that have the potential to increase our understanding of disease pathology [49].
Therefore, we focused on potential functional consequences of the identified association signals. We
reported several genes for which expression is regulated by rs2168518 and we even revealed small
genetic sub-signals that regulate multiple eGenes. The linkage of eGenes with phenotype association
signals at the 15q24.1 locus reveals three main findings: First, the association signals of AMD and
the blood pressure-related phenotypes colocalize to a great extent with the expression regulation of
CYP1A1, for example, in the tibial artery and subcutaneous and visceral omentum adipose tissue.
Since CYP1A1 is not completely independent in its regulation of CSK and ULK3, these genes also show
a colocalization in some tissues. Interestingly, CYP1A1 appears not to be expressed in the human
retina as reported by three recent RNA-sequencing studies [50–52]. It should be mentioned that the
retina is a highly specialized tissue consisting of a variety of cell types, including at least 60 distinct
types of neurons [53]. Drawing conclusions from current single cell RNA-sequencing studies of the
retina is still difficult due to the low sample sizes and high inter-sample variability [51,54–56]. Further,
the transcriptomes of the retinal supporting system, including retinal pigment epithelial cells and
choroidal vasculature, are not well investigated on the transcriptome level so far [51,57]. The second
main finding of the linkage analysis of eGenes with phenotype association signals at 15q24.1 revealed
that the expression regulation of RPP25 colocalizes with the association signal of “Birth weight of first
child” in several tissues. Therefore, this finding appears to have a different molecular mechanism
than the other phenotypes with an association signal at this locus. Third, there is no gene for which
expression regulation colocalizes with the GWAS associations in the studies “Creatinine in urine” and
“Sodium in urine”.
CYP1A1, a member of the cytochrome p450 enzyme family, has an important role in the
detoxification reaction of polycyclic aromatic hydrocarbons, found, for example, in tobacco smoke and
hence is involved in oxidative stress responses [58,59]. Oxidative stress has been noted as an important
player in AMD pathogenesis [60]. In the pre-GWAS era, this had led to directly investigate associations
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between genes involved in oxidative stress defenses and AMD [61]; however, so far, AMD has not
been linked to CYP1A1. Interestingly, in an animal model for AMD retinal CYP1A1 mRNA expression
was found to be decreased when compared to control animals [62]. This agrees with our eQTL results.
There is also evidence that induction of CYP1A1 is a risk factor for hypertension [63]. This in turn may
explain the protective effect of the genetic variant rs2168518, which reduces the expression of CYP1A1
on blood pressure. Further investigations on the impact of CYP1A1 expression in cell lines with a
defined genotype after oxidative stress induction could be an interesting field of future research.
Another interesting, although elusive finding in our study, is the gender-specificity of the rs2168518
association with AMD. There are three phenotypes colocalizing with the rs2168518-associated signal
including AMD, blood pressure, and hearing difficulty/problems with background noise. While there
is no gender-specific association with blood pressure, the AMD association is male-specific and the
hearing difficulty association signal shows a female specificity. This supports a potential gender-specific
regulation mechanism at this locus. However, our approach was not feasible to draw additional
conclusions regarding gender-specific eQTL effects as the sample size and statistical power in the eQTL
dataset was insufficient. Nevertheless, an association between the aforementioned polymorphism and
certain blood pressure medications, which was calculated separately in females and males, colocalizes
with different eGenes in each gender. While the association signal in females colocalizes mainly with
MPI and ULK3, the association signal in males colocalizes predominantly with CYP1A1 and CSK.
This fits the colocalization of CYP1A1 expression with the association signal of AMD and the fact that
we could find an association only in male AMD patients. It should be noted, however, that so far this
is purely speculative and requires further analyses. Nonetheless, alterations in the binding sites for
the sex determination TFs SRY and SOX9 [43] as well as for the X chromosomal TF ZFX indicated
that gender-specific regulation processes could be involved at this locus. As these aspects cannot be
clarified conclusively at the present time, it is currently not recommended to introduce rs2168518
genotyping into clinical practice.
An in-depth characterization of a novel AMD-associated locus at 15q24.1 reveals several effects
with potential impact on AMD pathogenesis. Importantly, we described an intriguing link between
gene expression regulation of CYP1A1 and CNV as well as blood pressure. Together these findings close
the gap between functional evidence from previous studies and the genetics of AMD. Furthermore,
several altered TF binding sites at 15q24.1 could contribute to gender specificity of the AMD association
at this locus. Finally, our data emphasize the importance to identify promising candidate genes
at an associated locus in order to reach a better insight into disease mechanisms behind a genetic
association signal.
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